Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

67 protocols found



Protocol No. Title Status
A011104 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer Open
A011106 ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study Open
A011202 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Open
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Open
A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
A211102 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women Open
A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
E2112 A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer Open
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy VS Capecitabine in Patients with Residual Triple-Negative Basal Like Breast Cancer following Neoaduvant Chemotherapy Open
EAI142 [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer Open
NCI9782 A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors Open
NRGBR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or w/o Carboplatin for Node+ or High-Risk Node- Triple-Neg Invasive Breast Cancer Open (affiliates only)
NSABPB55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo Versus Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Open (affiliates only)
RTOG1119 Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer-A Collaborative Study of NRG Oncology and KrogPha Open
RTOG1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 cm residual Invasive Cancer or Positive Lymph Node Open
S1501 S1501: Prospective Evaluation in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III Open (affiliates only)
UW13043 A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014 Open
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open
UW13060 Pilot study of short-term bisphosphonate administration as chemopreventive for breast cancer via engagement of gamma-delta T cells Open
UW13061 Pilot Study: Comparison of rpFNA and CNB for Breast Tissue Collection for Chemopreventive Studies Open
UW13089 A Randomized Controlled Trial Evaluating the Impact of Pre-Operative Web-based Breast Cancer Information on the Quality of Patient Decision-Making Open
UW14035 Correlation of tumorigenic properties in early stage breast cancer: an investigation of tumor types, mitotic phenotypes, and tumor microenvironment interactions Open
UW15026 Breast MR/PET Imaging Protocol Development and Validation Open
UW15048 Monitoring microwave ablation of breast tumors via real-time microwave imaging Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW15078 An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) Open
UW15106 Genomic analysis of long-term survivors with metastatic cancer Open
UW15114 A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers with Nuclear Epidermal Growth Factor Receptor Open
UW15128 PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer) Open
UW16005 Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma Open
UW16009 Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 Open
UW16029 Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice Open (affiliates only)
UW16044 A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024 Open
UW16050 A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Open
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
UW16063 Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect Open
UW16073 Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with Er-Positive, HER2-negative Early Breast Cancer Open
UW16083 A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer Open
UW16088 A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial) Open
UW16106 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response Open
UW16107 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors Open
UW16112 A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW16137 An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas Open
UW16141 Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Open
UW16151 Pharmacodynamic biomarkers of standard anti-microtubule drugs as assessed by early tumor biopsy Open
UW17034 [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer Open
UW17038 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial:(CANVAS Trial) Open
UW17055 A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors Open
UW17064 A Phase 2, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Open
UW17092 Intraoperative use of the OTIS (Optical Tissue Imaging System) in Surgically Excised Lumpectomy Breast Tissue Open
UW17098 Phase 1 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW17125 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial (AFT-25) Open
UW17147 Pre-Visit Planning in Palliative Care Open
UW17152 An Open-Label Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification Open
UW18036 Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations Open